Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has reported E.P.S. of $0.70 for its third fiscal quarter (ending September 30) versus $-0.29 for the same period a year ago — a decline of -341%. For the latest four quarters through September 30, E.P.S. were $1.08 compared to $0.47 a year ago — an increase of 130%.
Recent Price Action
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock closed at $34.70 on 11/4/24 after a large increase of 2.1%. Moreover, above average trading volume at 132% of normal accompanied the advance. The stock has risen 2.3% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Supernus Pharmaceuticals has a neutral Power Rating of 47 and a slightly negative Appreciation Score of 39, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment